ArticleJournal of thoracic disease2017

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

Zheng Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.